Atrial and ventricular septal defects can safely be closed by percutaneous intervention

Journal of Interventional Cardiology

Volumn 18, Issue 6, 2005, Pages 515-522

  Hein, Ralph ^a   Büscheck, Franziska ^a   Fischer, Evelyn ^a   Leetz, Michaela ^a   Bayard, Margareth Taaffe Yves ^a   Ostermayer, Stefan ^a   Reschke, Madlen ^a   Lang, Klaus ^a   Römer, Albrecht ^a   Wilson, Neil ^a   Sievert, Horst ^a  

^a CARDIOVASCULAR CENTER FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHETERIZATION; CONFERENCE PAPER; DEVICE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; IMPLANT; OCCLUSION; PRIORITY JOURNAL; TECHNIQUE;

HEART CATHETERIZATION; HEART SEPTAL DEFECTS, ATRIAL; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; SAFETY;

EID: 28444462483     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2005.00094.x     Document Type: Conference Paper

References (35)

1. Mas JL, Arquizan C, Lamy C. Patent Foramen Ovale and Atrial Septal Aneurysm Study Group: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm or both. N Engl J Med 2001;345:1740-1746.
2. Mas JL, Zuber M. Patent Foramen Ovale and Atrial Septal Aneurysm Study Group: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm or both and cryptogenic stroke or transient ischemic attack. Am Heart J 1995;130:1083-1088.
3. Homma S, Sacco RL, Di Tullio MR, et al. PFO in Cryptogenic Stroke Study (PICCS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105(22):2625-2632.
4. Comess KA, DeRook FA, Beach KW, et al. Transesophageal echocardiography and carotid ultrasound in patients with cerebral ischemia: Prevalence of findings and recurrent stroke risk. J Am Coll Cardiol 1994;23(7):1598-1603.
5. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomized controlled trial. Lancet 2003;362(9397):1691-1698.
6. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: A systematic review. Ann Intern Med 2003;139(9):753-760.
7. Bogousslavsky J, Garazi S, Jeanrenaud X, et al. Stroke recurrence in patients with patent foramen ovale: The Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 1996;46(5):1301-1305.
8. Stone DA, Godard J, Corretti MC, et al. Patent foramen ovale: Association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J 1996;131:158-161.
9. Wahl A, Meier B, Haxel B, et al. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology 2001;57:1330-1332.
10. Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004;62:1399-1401.
11. Azerbal B, Tobis J, Suh W, et al. Association of interatrial shunts and migraine headaches. J Am Coll Cardiol 2005;45(4):489-492.
12. Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005;45(4):493-495.
13. Divekar A, Gaamangwe T, Shaikh N, et al. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol 2005;45(8):1213-1218.
14. Berger F, Vogel M, Alexi-Meskishvili V, et al. Comparison of results and complications of surgical and Amplatzer device closure of atrial septal defects. J Thorac Cardiovasc Surg 1999:118:674-680.
15. Du ZD, Hijazi ZM, Kleinman CS, et al. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults. Results of a multicenter nonrandomized trial. J Am Coll Cardiol 2002;39:1836-1844.
16. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Comparison of atrial septal defect closure using amplatzer septal occluder with surgery. Pediatr Cardiol 2002;23(1):36-40).
17. Omeish A, Hijazi ZM. Transcatheter closure of atrial septal defects in children and adults using the Amplatzer Septal Occluder. J Interven Cardiol 2001;14:37-44.
18. Carminati M, Giusti S, Hausdorf GA, et al. European multicentric experience using the CardioSEAL and STARFlex double umbrella devices to close interatrial communications holes within the oval fossa. Cardiol Young 2000;10(5):519-526.
19. Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol 2002;39:1061-1065.
20. Vincent RN, Raviele AA, Diehl HJ. Single-center experience with the Helex septal occluder for closure of atrial septal defects in children. J Interven Cariol 2003;16:79-82.
21. Purcell IF, Brecker SJ, Ward DE. Closure of defects of the atrial septum in adults using the Amplatzer device: 100 consecutive patients in a single center. Clin Cardiol 2004;27(9):509-513.
22. Krumsdorf U, Ostermayer S, Billinger K. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004;43(2):302-309.
23. Wang HS, Qian MY, Zhang ZW. Applying interventional treatment for the atrial septal defect in 165 children under five years of age. Zhonghua Er Ke Za Zhi 2005;43(5):373-376.
24. Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders. J Am Coll Cardiol 2005;45(4):505-507.
25. Du ZD, Koenig P, Cao QL, et al. Comparison of transcatheter closure of secundum atrial septal defect using the Amplatzer septal occluder associated with deficient vs. sufficient rims. Am J Cardiol 2002;90(8):865-869.
26. Lock JE, Block PC, McKay RG, et al. Transcatheter closure of ventricular septal defects. Circulation 1988;78:361-368.
27. van der Velde ME, Sanders SP, Keane JF, et al. Transesophageal echocardiographic guidance of transcatheter ventricular septal defect closure. J Am Coll Cardiol 1994;23:1660-1665.
28. Sideris EB, Walsh KP, Haddad JL, et al. Occlusion of congenital ventricular septal defects by the buttoned device. Heart 1997;77:276-279.
29. Kalra GS, Verma PK, Dhall A, et al. Transcatheter device closure of ventricular septal defects: Immediate results and intermediate-term follow-up. Am Heart J 1999;138:339-344.
30. Chessa M, Carminati M, Cao QL, et al. Transcatheter closure of congenital and acquired muscular ventricular septal defects using the Amplatzer device. J Invasive Cardiol 2002;14:322-327.
31. Ewert P, Kretschmar O, Peters B, et al. Transcatheter closure of congenital ventricular septal defects. Z Kardiol. 2004;93(2):147-155.
32. Knauth AL, Lock JE, Perry SB, et al. Transcatheter device closure of congenital and postoperative residual ventricular septal defects. Circulation 2004;110(5):501-507.
33. Arora R, Trehan V, Thakur AK, et al. Transcatheter closure of congenital muscular ventricular septal defect. J Interven Cardiol 2004;17(2):109-115.
34. Holzer R, Balzer D, Cao QL, et al. Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: Immediate and mid-term results of a U.S. registry. J Am Coll Cardiol 2004;43(7):1257-1263.
35. Michel-Behnke I, Le TP, Waldecker B, et al. Percutaneous closure of congenital and acquired ventricular septal defects-considerations on selection of the occlusion device. J Interven Cardiol 2005;18(2):89.